-
Mashup Score: 52
Intensive BP management to <130 mm Hg did not improve outcomes in AIS patients undergoing EVT within 6 h and achieved successful recanalisation. The optimal BP management strategies require further investigation.
Source: www.thelancet.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 1Explorations in Neurointervention - Endovascular Today - 15 day(s) ago
This year marks the 10th anniversary of the publication of five landmark endovascular thrombectomy trials—MR CLEAN, ESCAPE, SWIFT PRIME, EXT
Source: evtoday.comCategories: General Medicine News, NephrologyTweet-
RT @ShashvatDesai: Explorations in Neurointervention on @EVToday https://t.co/7o9knXrbQI @AshuPJadhav
-
-
Mashup Score: 32Neuroprotection: Where Do We Stand? - Endovascular Today - 15 day(s) ago
Advantages, disadvantages, what we can learn from the most common neuroprotection strategies, and future directions for the field.
Source: evtoday.comCategories: General Medicine News, NephrologyTweet-
Neuroprotection: Where Do We Stand? on @EVToday https://t.co/B6pkWRc7Sk https://t.co/RBBTgZsP4e
-
-
Mashup Score: 4
A summary of preclinical evaluation methods for neuroendovascular devices, including in vitro techniques, 3D-printed vascular models, in silico simulations, and in vivo models.
Source: evtoday.comCategories: General Medicine News, NephrologyTweet-
Recent Advances in Preclinical Testing of Novel Devices on @EVToday https://t.co/gC4qbJIleF https://t.co/87ZI9NpeWh
-
-
Mashup Score: 4Detection, Treatment, and Future Prospects for Distal and Medium Vessel Occlusions - Endovascular Today - 15 day(s) ago
A conversation on data from recent trials, lessons learned for future study, definitions and imaging protocols, how treatment can be refined, and more.
Source: evtoday.comCategories: General Medicine News, NephrologyTweet-
Detection, Treatment, and Future Prospects for Distal and Medium Vessel Occlusions on @EVToday https://t.co/3OIg06I9Wa
-
-
Mashup Score: 32Neuroprotection: Where Do We Stand? - Endovascular Today - 15 day(s) ago
Advantages, disadvantages, what we can learn from the most common neuroprotection strategies, and future directions for the field.
Source: evtoday.comCategories: General Medicine News, NephrologyTweet-
Neuroprotection: Where Do We Stand? on @EVToday https://t.co/B6pkWRc7Sk https://t.co/RBBTgZsP4e
-
-
Mashup Score: 19Middle Meningeal Artery Embolization in the Treatment of Chronic Headaches - Endovascular Today - 15 day(s) ago
Exploring middle meningeal artery embolization as a promising experimental therapy for chronic headaches, emphasizing the need for further clinical trials to validate efficacy, optimize patient selection and the technical approach, and ensure safety.
Source: evtoday.comCategories: General Medicine News, NephrologyTweet-
Middle Meningeal Artery Embolization in the Treatment of Chronic Headaches on @EVToday https://t.co/pHKXouLJIh https://t.co/NSFNyNzgrI
-
-
Mashup Score: 5Bridging the implementation gap in non-communicable diseases - 16 day(s) ago
Nature Medicine – A focus on implementation for non-communicable diseases could help to deliver a 50% reduction in the probability of premature mortality worldwide by 2050.
Source: www.nature.comCategories: General Medicine News, NephrologyTweet-
Bridging the implementation gap in non-communicable diseases https://t.co/q7DN6qFbx1 https://t.co/kQi4OePLFD
-
-
Mashup Score: 5
Background Craniotomy for subdural hematoma (SDH) in elderly patients with comorbidities can be challenging. The Subdural Evacuating Port System (SEPS; Medtronic, Minneapolis, MN) offers a less invasive alternative, while middle meningeal artery embolization (MMAE) has shown effectiveness in preventing SDH recurrence. We evaluated the combined effectiveness of SEPS+MMAE for chronic SDH (cSDH) treatment. Methods Retrospective database reviews were conducted. Demographic, comorbidity, procedural, and outcomes data were analyzed. cSDH resolution was tracked by measuring hematoma volumes on noncontrast computed tomograms pre-SEPS+MMAE, 24–48 hours post-SEPS+MMAE, and 6–8 weeks afterward (follow-up-SEPS+MMAE). Results Our study included 114 patients (median age: 77 years (interquartile range (IQR): 69–83 years); men: women=74:40) with 134 cSDHs treated with SEPS+MMAE were included. Median pre-SEPS+MMAE cSDH volume was 122.9 mL (88–152.4 mL) with midline shift of 6 mm (3.4–9.5 mm). Most MMAE
Source: jnis.bmj.comCategories: General Medicine News, NephrologyTweet-
Effectiveness of subdural evacuating port system (SEPS) and middle meningeal artery embolization (MMAE) for chronic subdural hematomas – a multicenter experience https://t.co/cEI9E2njb7
-
-
Mashup Score: 7Can CTA-based Machine Learning Identify Patients for Whom Successful Endovascular Stroke Therapy is Insufficient? - 16 day(s) ago
BACKGROUND AND PURPOSE: Despite advances in endovascular stroke therapy (EST) devices and techniques, many patients are left with substantial disability, even if the final infarct volumes (FIVs) remain small. Here, we evaluate the performance of a machine learning (ML) approach using pre-treatment CT angiography (CTA) to identify this cohort of patients that may benefit from additional interventions. MATERIALS AND METHODS: We identified consecutive large vessel occlusion (LVO) acute ischemic stroke (AIS) subjects who underwent EST with successful reperfusion in a multicenter prospective registry cohort. We included only subjects with FIV<30mL and recorded 90-day outcome (modified Rankin scale, mRS). A deep learning model was pre-trained and then fine-tuned to predict 90-day mRS 0-2 using pre-treatment CTA images (DSN-CTA model). The primary outcome was the predictive performance of the DSNCTA model compared to a logistic regression model with clinical variables, measured by the area un
Source: www.ajnr.orgCategories: General Medicine News, NephrologyTweet-
Can CTA-based Machine Learning Identify Patients for Whom Successful Endovascular Stroke Therapy is Insufficient? https://t.co/2nll285BA3
-
Early intensive blood pressure management after endovascular treatment in ischaemic stroke (IDENTIFY): a multicentre, open-label, blinded-endpoint, randomised controlled trial - The Lancet Regional Health – Western Pacific https://t.co/kHsM8nDaZp https://t.co/Jb1zFB42v5